A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment
Status:
Completed
Trial end date:
2006-09-26
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacokinetics and tolerability of a single dose of GW406381 in
subjects with moderate hepatic impairment in comparison to matched healthy volunteers. The
hepatically impaired and healthy groups will be given a single 20 mg oral dose of GW406381.
Blood samples for PK analysis will be collected pre-dose and over the 72 hours post dosing.
Subjects will be housed from the evening before dosing until 24 hours after dosing. A
follow-up visit will be conducted between 7 to 10 days from the last dose of study drug.